Several LSD1 inhibitors structurally based on Tranylcypromine scaffold (e.g., ORY-2001, ORY-1001, and TAK-418) are currently in clinical trials for cancer therapy, highlighting its emerging potential in oncology (Zheng et al., 2016; Song et al., 2022, 2025; Sheikh et al., 2025). This evidence concerns the gene KDM1A and cancer.